Core Viewpoint - TME Pharma has successfully extended the maturity of its loans by 12 months, providing the company with a financial runway into Q2 2027, which reflects lenders' confidence in the company's management and its potential for success [2][3][5]. Financial Developments - Certain lenders have agreed to extend the maturity of loans totaling approximately €2.06 million, which represents 93.2% of the total loans from May and August 2025 [3]. - The extension includes an increase in the term of the warrants until December 31, 2030, with lenders receiving 30% additional warrants at the same strike prices of €0.10 and €0.11 [3]. - If all new warrants are fully exercised, TME Pharma could receive an additional amount of approximately €678,000 through the issuance of 6,584,116 shares, resulting in approximately 7% dilution [3]. Bond Redemption - TME Pharma plans to redeem bonds early on March 11 for bondholders who opted not to extend, amounting to €163,562.50 including interest [4]. Strategic Focus - The company is focused on accelerating discussions with partners to optimize the value of its lead compounds, NOX-A12 and NOX-E36, following the financial stability gained from the loan extension [5]. - Under the leadership of the new CEO, TME Pharma is undergoing a strategic restructuring to unlock the value of its key assets [7]. Clinical Development - NOX-A12 is currently in a Phase 1/2 clinical trial (GLORIA) for newly diagnosed brain cancer patients, with FDA and German BfArM approvals for a randomized Phase 2 trial in glioblastoma [6][8]. - NOX-E36 is being evaluated for ophthalmic diseases, focusing on well-tolerated therapies with anti-fibrotic effects [6]. Business Strategy - The company is exploring potential acquisitions and partnerships in stable, profitable businesses to create a fundamentally profitable corporate structure [11]. - TME Pharma is also pursuing alternative funding sources, having raised €1.7 million in May 2025, including €500,000 from the new CEO [13].